Splanchnic Vein Thrombosis in Inflammatory Bowel Disease: An Observational Study from the ENEIDA Registry and Systematic Review

J Clin Med. 2023 Nov 28;12(23):7366. doi: 10.3390/jcm12237366.

Abstract

Background: Thromboembolic events are frequent among patients with inflammatory bowel disease (IBD). However, there is little information on the prevalence, features and outcomes of splanchnic vein thrombosis (SVT) in patients with IBD.

Aims: To describe the clinical features and outcomes of SVT in patients with IBD and to perform a systematic review of these data with published cases and series.

Methods: A retrospective observational study from the Spanish nationwide ENEIDA registry was performed. A systematic search of the literature was performed to identify studies with at least one case of SVT in IBD patients.

Results: A new cohort of 49 episodes of SVT from the Eneida registry and 318 IBD patients with IBD identified from the literature review (sixty studies: two multicentre, six single-centre and fifty-two case reports or case series) were analysed. There was a mild predominance of Crohn's disease and the most frequent clinical presentation was abdominal pain with or without fever followed by the incidental finding in cross-sectional imaging techniques. The most frequent SVT location was the main portal trunk in two-thirds of the cases, followed by the superior mesenteric vein. Anticoagulation therapy was prescribed in almost 90% of the cases, with a high rate of radiologic resolution of SVT. Thrombophilic conditions other than IBD itself were found in at least one-fifth of patients.

Conclusions: SVT seems to be a rare (or underdiagnosed) complication in IBD patients. SVT is mostly associated with disease activity and evolves suitably when anticoagulation therapy is started.

Keywords: inflammatory bowel disease; outcome; prevalence; splanchnic vein thrombosis.

Publication types

  • Review

Grants and funding

HM received a research grant from the Catalan Society of Digestive Diseases (Beca d’Intensificació per la Recerca de la Societat Catalana de Digestologia 2021) and MP received a research grant from the Catalan Society of Digestive Diseases (Beca d’Iniciació a la Recerca de la Societat Catalana de Digestologia 2022) which partly supported this study. The ENEIDA registry of GETECCU is currently supported by Biogen, Takeda, Pfizer, and Janssen.